


## Supplementary Material

## Supplementary Figure 1. Percentage of patients with enthesitis (a) overall analysis; (b) remainder analysis or dactylitis; (c) overall analysis; (d) remainder analysis



Data shown as percentage of patients with enthesitis or dactylitis at baseline, 12 months, and 36 months (LOCF).

Error bars represent 95% CI.

The overall analysis included patients switching/stopping their original treatment during the 3-year observation period. The remainder analysis reflects 3-year data from assessments for patients still under initial treatment at 3 years.

BL, baseline; CI, confidence intervals; TNFi, tumour necrosis factor inhibitors; UST, ustekinumab

**Supplementary Table 1. Mean swollen joint counts at baseline, 1 year and 3 years for overall patients (n=895) and remainers (n=437) (LOCF analysis)**

Mean (SD)[95%CI]	UST overall (n=439)	TNFi overall (n=456)	UST remainers (n=219)	TNFi remainers (n=218)
Swollen joint count at baseline	n=439 5.8 (8.1) [5.0; 6.6]	n=456 5.9 (7.6) [5.2; 6.7]	n=219 6.1 (8.5) [4.9; 7.2]	n=218 7.0 (8.7) [5.8; 8.3]
Swollen joint count at 1 year Change from baseline at 1 year	n=298 1.8 (3.8) [1.3; 2.2] -4.4 (7.9) [-5.5; -3.5]	n=293 1.2 (2.4) [0.9; 1.5] -4.7 (6.9) [-5.5; -3.9]	n=190 1.5 (3.5) [1.0; 2.0] -4.7 (8.3) [-5.9; -3.5]	n=185 0.9 (1.9) [0.7; 1.2] -5.7 (7.8) [-6.9; -4.6]
Swollen joint count at 3 years Change from baseline at 3 years	n=384 2.0 (4.8) [1.5; 2.4] -3.9 (7.9) [-4.7; -3.1]	n=373 1.5 (4.2) [1.1; 2.0] -4.4 (7.6) [-5.2; -3.6]	n=204 0.7 (2.4) [0.3; 1.0] -5.4 (8.2) [-6.5; -4.3]	n=196 0.9 (4.0) [0.3; 1.5] -6.2 (9.0) [-7.4; -4.9]

The overall analysis included patients switching/stopping their original treatment during the 3-year observation period. The remainder analysis reflects 3-year data from assessments for patients still under initial treatment at 3 years.

CI, confidence interval; LOCF, last observation carried forward; SD, standard deviation; TNFi, tumour necrosis factor inhibitors; UST, ustekinumab